Navigation Links
Immtech Investor Conference Call Scheduled for February 11, 2008
Date:2/6/2008

release contains forward-looking statements regarding Immtech's business, including the future prospects for PCP. Except for historical information, the matters discussed in this press release are forward-looking statements and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the following: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidates, including PCP; (vii) the success of Immtech's clinical trials; (viii) Immtech's dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to contract with a third party to manufacture its drug candidates at reasonable costs; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) Immtech's potential exposure to significant product liability.

Additional risks are discussed in Immtech's current filings with the Securities and Exchange Commission. Although Immtech believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and Immtech undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
2. Immtech to Present at The Bank of Montreal Healthcare Conference
3. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
5. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
6. PharmAthene to Present at the BIO CEO & Investor Conference 2008
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Rigel to Present at BIO CEO & Investor Conference
11. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous ... quarter ended June 30, 2015, corporate highlights, and ... report are available at www.sedar.com ,  ... "RepliCel expects to launch its RCS-01 ...
(Date:8/27/2015)... ... ... Capital Edge Consulting , a nationwide consulting firm that specializes in helping ... one of the top 5000 companies listed on the 2015 Inc. 5000 , ... is truly an honor to be recognized as one of America’s fastest growing companies. ...
(Date:8/27/2015)... Calif. , Aug. 27, 2015  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... conferences in the month of September.  ... present at Rodman & Renshaw,s 17th Annual Global Investment ... PT at the St. Regis Hotel in ...
(Date:8/27/2015)... ... , ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately ... for the three years through 2014. Being named to the Inc. 5000 list designates ... country. , “We are thrilled to make the Inc. 5000 list for 2015,” ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... Group (USA) Reports Second Quarter and Six-Month Results -- NEW YORK, Aug. 19 /PRNewswire-Asia/ -- ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
... SAN FRANCISCO, Aug. 19 Jennerex, Inc., a ... commercialization of first-in-class, breakthrough targeted oncolytic products for ... subscribed private placement financing with aggregate gross proceeds ... from this transaction will be used to advance ...
... offers a new transfection kit ideal for biotherapeutic protein ... new Trans IT-PRO™ Kit will decrease time to ... transient transfection. Trans IT-PRO™ Kit uses animal origin ... in suspension CHO and 293 derived cells. Since it ...
Cached Biology Technology:Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 2Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 3Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 4Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 5Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 6Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 7Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 8Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 9Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 10Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 11Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 12Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million 2
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... SHENZHEN, China , 31. Juli 2015 Die ... ) wird von BGI veranstaltet und findet vom ... Shenzhen, China , statt. ... Jubiläum. Seit ihrem Start 2006 ist die ICG ... Bereich „omik" geworden. Sie ist eines der dynamischsten, ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... Rensselaer Polytechnic Institute announced today a $480,000 gift ... the James P. Ferris Fellowship in Astrobiology, which will ... research in the interdisciplinary field of astrobiology. The fellowship ... of chemistry and chemical biology, currently a senior research ...
... a fully functional body: as embryos develop and grow, they ... size of the embryo. The exact mechanism underlying this fundamental ... researchers from EMBL Heidelberg is now one step closer to ... vertebrae in a mouse embryo is controlled by how the ...
... androgen deprivation therapies to prevent precancerous prostate abnormalities developing ... men with precancers with specific genetic alterations, according to ... Cancer Discovery , a journal of the American Association ... of prostate cancer cells are very dependent on signals ...
Cached Biology News:Rensselaer awarded gift to establish fellowship in astrobiology 2Sync to grow 2Preventing prostate cancer through androgen deprivation may have harmful effects 2
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
SHEEP ANTI BOVINE LACTOPEROXIDASE...
... and flexibility press-to-seal silicone isolators can be ... researcher. They are available either pre-cut to ... that can be easily trimmed to prepare ... non-cytotoxic and can be used to isolate ...
Request Info...
Biology Products: